2011
Central and Peripheral Administration of Compound 21 Elicits Cerebroprotective Effects in Ischemic Stroke
Joseph J, Regenhardt R, Mecca A, Patel N, Steckelings U, Unger T, Katovich M, Sumners C. Central and Peripheral Administration of Compound 21 Elicits Cerebroprotective Effects in Ischemic Stroke. The FASEB Journal 2011, 25: lb576-lb576. DOI: 10.1096/fasebj.25.1_supplement.lb576.Peer-Reviewed Original ResearchMiddle cerebral artery occlusionIpsilateral gray matterArtificial cerebrospinal fluidInfarct sizeMCAO inductionIschemic strokeNeurological deficitsControl ratsAdult male Sprague-Dawley ratsAngiotensin type 2 receptorGray matterMale Sprague-Dawley ratsSpecific AT2R agonistCerebral artery occlusionExert beneficial actionsSprague-Dawley ratsType 2 receptorACSF controlsCerebroprotective effectArtery occlusionPeripheral administrationAT2R agonistIP administrationEndothelin-1Intracerebroventricular infusion
2007
Angiotensin‐(1–7) prevents cardiac remodeling during angiotensin II‐induced hypertension
Grobe J, Mecca A, Lingis M, Shenoy V, Bolton T, Machado J, Speth R, Raizada M, Katovich M. Angiotensin‐(1–7) prevents cardiac remodeling during angiotensin II‐induced hypertension. The FASEB Journal 2007, 21: a896-a897. DOI: 10.1096/fasebj.21.6.a896-d.Peer-Reviewed Original ResearchAng IICardiac remodelingBlood pressureInterstitial fibrosisMyocyte hypertrophyMale Sprague-Dawley ratsAng II infusionAnti-remodeling effectsEnd-organ damageRenin-angiotensin systemSprague-Dawley ratsII infusionAng receptorsAngiotensin receptorsAngiotensin IIMyocardial fibrosisRat modelMyocyte diameterEnzyme 2Receptor populationAngHypertensionFibrosisSignificant attenuationLentiviral delivery
2006
Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7)
Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). AJP Heart And Circulatory Physiology 2006, 292: h736-h742. PMID: 17098828, DOI: 10.1152/ajpheart.00937.2006.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAngiotensin IAngiotensin IIAnimalsBlood PressureCardiomegalyDisease Models, AnimalFibrosisHeartHypertensionMaleMyocardiumPeptide FragmentsProto-Oncogene MasProto-Oncogene ProteinsRatsRats, Sprague-DawleyReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Receptors, G-Protein-CoupledTime FactorsTransforming Growth Factor betaVentricular RemodelingConceptsRenin-angiotensin systemCardiac remodelingChronic infusionBlood pressureAng IIHeart failureInterstitial fibrosisAngiotensin IIMyocyte hypertrophyHyperactive renin-angiotensin systemAng II type 1Adult Sprague-Dawley ratsEffects of AngSubsequent heart failureOverexpression of angiotensinAcute myocardial infarctionMajor risk factorFormation of AngSprague-Dawley ratsCardiac tissueSubgroup of animalsChronic hypertensionAng receptorsMyocardial infarctionRisk factorsChronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension
Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension. AJP Heart And Circulatory Physiology 2006, 290: h2417-h2423. PMID: 16415071, DOI: 10.1152/ajpheart.01170.2005.Peer-Reviewed Original ResearchConceptsDOCA-salt modelBlood pressureCardiac hypertrophyCardiac fibrosisCardiac remodelingDeoxycorticosterone acetate pelletsDOCA-salt animalsBlood pressure responseCarotid artery cannulationDOCA-salt treatmentTail-cuff methodWk of treatmentPerivascular collagen depositionSprague-Dawley ratsNormal drinking waterAngiotensin fragmentsChronic angiotensinDOCA animalsAngiotensin infusionArtery cannulationPerivascular fibrosisSham surgeryAngiotensin IIOsmotic minipumpsMyocyte diameter